ARTICLE | Deals
Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform
Denali to advance lead Parkinson’s program, BBB-penetrant candidates with cash infusion from Biogen
August 7, 2020 1:29 AM UTC
Updated on Aug 8, 2020 at 1:44 AM UTC
With more than $1 billion in upfront money via its biggest deal yet, Denali now has enough firepower to bring its lead program into late-stage testing and validate its CNS delivery technology in the clinic.
The deal with Biogen Inc. (NASDAQ:BIIB) also helps Denali Therapeutics Inc. (NASDAQ:DNLI) derive value from its Transport Vehicle (TV) technology in areas where it wasn’t planning to invest. ...
BCIQ Target Profiles